PMID- 33899766
OWN - NLM
STAT- MEDLINE
DCOM- 20220225
LR  - 20230927
IS  - 1533-0311 (Electronic)
IS  - 0193-1091 (Linking)
VI  - 43
IP  - 12
DP  - 2021 Dec 1
TI  - Correlation of FISH and PRAME Immunohistochemistry in Ambiguous Superficial 
      Cutaneous Melanocytic Proliferations.
PG  - 913-920
LID - 10.1097/DAD.0000000000001951 [doi]
AB  - Preferentially expressed antigen in melanoma (PRAME) is a tumor-associated 
      repressor of retinoic acid signaling which is expressed in melanoma and has 
      emerged as a potential biomarker for malignant behavior in melanocytic neoplasms. 
      Although ancillary molecular techniques such as fluorescence in situ 
      hybridization (FISH) are established techniques in the diagnosis of problematic 
      cutaneous melanocytic proliferations, they are expensive, time-consuming, and 
      require appropriate infrastructure, which places them out of reach of some 
      laboratories. The advent of readily available commercial antibodies to PRAME has 
      the potential to provide a more accessible alternative. The aim of this study was 
      to determine whether immunohistochemistry for PRAME could serve as a surrogate 
      for FISH analysis in a subgroup of challenging superficial melanocytic 
      proliferations. Cases which had previously been submitted for FISH analysis were 
      stained for PRAME and interpreted by a panel of at least 3 dermatopathologists is 
      a blinded fashion. Of a study set of 55 cases, 42 (76%) showed a pattern of PRAME 
      immunostaining which was concordant with the cytogenetic interpretation, with an 
      unweighted kappa of 0.42 (representing mild-to-moderate agreement). Thus, 
      although there was a correlation between positive immunohistochemistry for PRAME 
      and abnormal findings on FISH analysis, in our view, the concordance was not 
      sufficient to enable PRAME immunohistochemistry to act as a surrogate for FISH 
      testing. Our findings reiterate the principle that interpretation of problematic 
      superficial melanocytic proliferations requires a synthesis of all the available 
      data, including clinical scenario, morphological features, immunohistochemistry, 
      and ancillary molecular investigations.
CI  - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Harvey, Nathan T
AU  - Harvey NT
AD  - Department of Anatomical Pathology, PathWest Laboratory Medicine, Perth, 
      Australia.
AD  - Division of Pathology and Laboratory Medicine, Medical School, University of 
      Western, Perth, Australia.
FAU - Peverall, Joanne
AU  - Peverall J
AD  - Department of Diagnostic Genomics, PathWest Laboratory Medicine, Perth, WA, 
      Australia; and.
FAU - Acott, Nathan
AU  - Acott N
AD  - Department of Anatomical Pathology, PathWest Laboratory Medicine, Perth, 
      Australia.
FAU - Mesbah Ardakani, Nima
AU  - Mesbah Ardakani N
AD  - Department of Anatomical Pathology, PathWest Laboratory Medicine, Perth, 
      Australia.
AD  - College of Science, Health, Engineering and Education, Murdoch University, Perth, 
      WA, Australia.
FAU - Leecy, Tamazin N
AU  - Leecy TN
AD  - Department of Anatomical Pathology, PathWest Laboratory Medicine, Perth, 
      Australia.
FAU - Iacobelli, Jean
AU  - Iacobelli J
AD  - Department of Anatomical Pathology, PathWest Laboratory Medicine, Perth, 
      Australia.
FAU - McCallum, Dugald
AU  - McCallum D
AD  - Department of Anatomical Pathology, PathWest Laboratory Medicine, Perth, 
      Australia.
FAU - Van Vliet, Chris
AU  - Van Vliet C
AD  - Department of Anatomical Pathology, PathWest Laboratory Medicine, Perth, 
      Australia.
FAU - Wood, Benjamin A
AU  - Wood BA
AD  - Department of Anatomical Pathology, PathWest Laboratory Medicine, Perth, 
      Australia.
AD  - Division of Pathology and Laboratory Medicine, Medical School, University of 
      Western, Perth, Australia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Dermatopathol
JT  - The American Journal of dermatopathology
JID - 7911005
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (PRAME protein, human)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Neoplasm/analysis
MH  - Biomarkers, Tumor/*analysis
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Melanoma/*diagnosis/pathology
MH  - Middle Aged
MH  - Skin Neoplasms/*diagnosis/pathology
MH  - Young Adult
COIS- The authors declare no conflicts of interest.
EDAT- 2021/04/27 06:00
MHDA- 2022/02/26 06:00
CRDT- 2021/04/26 09:05
PHST- 2021/04/27 06:00 [pubmed]
PHST- 2022/02/26 06:00 [medline]
PHST- 2021/04/26 09:05 [entrez]
AID - 00000372-202112000-00009 [pii]
AID - 10.1097/DAD.0000000000001951 [doi]
PST - ppublish
SO  - Am J Dermatopathol. 2021 Dec 1;43(12):913-920. doi: 10.1097/DAD.0000000000001951.